Servier and Teva have been fined for keeping a generic heart medication off the market.
Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.
The regulator says serial filers and time restraints are draining resources and staff.
The Supreme Court split the baby on "pay-for-delay" settlements, allowing them to continue but opening manufacturers that make them up to lawsuits.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.